Skip Nav Destination
Issues
1 January 2020
-
Cover Image
Cover Image
Genetic inactivation of the TGFβ pathway is observed in only about half of pancreatic ductal adenocarcinomas (PDAC), yet preventing TGFβ-mediated apoptosis of premalignant cells is thought to be important for PDAC development Huang and colleagues found that dysregulated expression of inhibitor of differentiation 1 (ID1) may explain this phenomenon Many PDAC cells exhibited high ID1 expression despite retaining TGFβ-pathway activity, and ID1 downregulation in PDAC cells led to apoptosis The pathologically sustained expression of ID1 appears to uncouple the TGFβ-mediated epithelial–mesenchymal transition from apoptosis, enabling PDAC cells to survive without genetic inactivation of the TGFβ pathway For details, please see the article by Huang and colleagues on page 142.Close Modal - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 2159-8274
EISSN 2159-8290
Issue Sections
In This Issue
In the Spotlight
Review
Research Articles
Author Choice
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Lawrence Fong; Andrew Hotson; John D. Powderly; Mario Sznol; Rebecca S. Heist; Toni K. Choueiri; Saby George; Brett G.M. Hughes; Matthew D. Hellmann; Dale R. Shepard; Brian I. Rini; Shivaani Kummar; Amy M. Weise; Matthew J. Riese; Ben Markman; Leisha A. Emens; Daruka Mahadevan; Jason J. Luke; Ginna Laport; Joshua D. Brody; Leonel Hernandez-Aya; Philip Bonomi; Jonathan W. Goldman; Lyudmyla Berim; Daniel J. Renouf; Rachel A. Goodwin; Brian Munneke; Po Y. Ho; Jessica Hsieh; Ian McCaffery; Long Kwei; Stephen B. Willingham; Richard A. Miller
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin; Lars D. Engstrom; Lauren Hargis; Andrew Calinisan; Ruth Aranda; David M. Briere; Niranjan Sudhakar; Vickie Bowcut; Brian R. Baer; Joshua A. Ballard; Michael R. Burkard; Jay B. Fell; John P. Fischer; Guy P. Vigers; Yaohua Xue; Sole Gatto; Julio Fernandez-Banet; Adam Pavlicek; Karen Velastagui; Richard C. Chao; Jeremy Barton; Mariaelena Pierobon; Elisa Baldelli; Emanuel F. Patricoin, III; Douglas P. Cassidy; Matthew A. Marx; Igor I. Rybkin; Melissa L. Johnson; Sai-Hong Ignatius Ou; Piro Lito; Kyriakos P. Papadopoulos; Pasi A. Jänne; Peter Olson; James G. Christensen
Author Choice
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
Carlotta Costa; Ye Wang; Amy Ly; Yasuyuki Hosono; Ellen Murchie; Charlotte S. Walmsley; Tiffany Huynh; Christopher Healy; Rachel Peterson; Shogo Yanase; Charles T. Jakubik; Laura E. Henderson; Leah J. Damon; Daria Timonina; Ioannis Sanidas; Christopher J. Pinto; Mari Mino-Kenudson; James R. Stone; Nicholas J. Dyson; Leif W. Ellisen; Aditya Bardia; Hiromichi Ebi; Cyril H. Benes; Jeffrey A. Engelman; Dejan Juric
Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis Drivers
Remi Klotz; Amal Thomas; Teng Teng; Sung Min Han; Oihana Iriondo; Lin Li; Sara Restrepo-Vassalli; Alan Wang; Negeen Izadian; Matthew MacKay; Byoung-San Moon; Kevin J. Liu; Sathish Kumar Ganesan; Grace Lee; Diane S. Kang; Charlotte S. Walmsley; Christopher Pinto; Michael F. Press; Wange Lu; Janice Lu; Dejan Juric; Aditya Bardia; James Hicks; Bodour Salhia; Frank Attenello; Andrew D. Smith; Min Yu
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
G. Aaron Hobbs; Nicole M. Baker; Anne M. Miermont; Ryan D. Thurman; Mariaelena Pierobon; Timothy H. Tran; Andrew O. Anderson; Andrew M. Waters; J. Nathaniel Diehl; Bjoern Papke; Richard G. Hodge; Jennifer E. Klomp; Craig M. Goodwin; Jonathan M. DeLiberty; Junning Wang; Raymond W.S. Ng; Prson Gautam; Kirsten L. Bryant; Dominic Esposito; Sharon L. Campbell; Emanuel F. Petricoin, III; Dhirendra K. Simanshu; Andrew J. Aguirre; Brian M. Wolpin; Krister Wennerberg; Udo Rudloff; Adrienne D. Cox; Channing J. Der
News in Brief
News in Depth
Research Watch
Chemotherapy
Chromatin
Clinical Trials
Drug Development
Drug Discovery
Drug Resistance
Gene Expression
Immunology
Immunotherapy
Mutations
Oncogenes
Prostate Cancer
Signaling
Skin Cancer
Telomeres
Acknowledgment to Reviewers
Advertisement